共 196 条
- [1] Fulton B(1996)Docetaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer Drugs 51 1075-92
- [2] Spencer CM(2000)Docetaxel: an update of its use in advanced breast cancer Drugs 59 621-51
- [3] Figgitt DP(2004)Docetaxel in the treatment of operable breast cancer Am J Cancer 3 325-32
- [4] Wiseman LR(1998)The taxoids: comparative clinical pharmacology and therapeutic potential Drugs 55 5-30
- [5] Keam SJ(1999)Recent progress in the clinical development of docetaxel (Taxotere) Semin Oncol 26 32-6
- [6] Scott LJ(1997)Antitumor activity of docetaxel Am J Health Syst Pharm 54 S2-6
- [7] Eisenhauer EA(1998)Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts Clin Cancer Res 4 1013-9
- [8] Vermorken JB(2003)A direct comparison of paclitaxel and docetaxel activities in human tumors [abstract no 655]. Proc Am Soc Clin Oncol 22 163-5
- [9] Hortobagyi GN(2002)Microtubuleassociated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study Clin Breast Cancer 3 341-206
- [10] Eckardt JR(2004)HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel Breast Cancer Res Treat 86 197-14